Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Head and Neck Cancer: Recent Advances and Future Directions
share announcement

Head and Neck Cancer: Recent Advances and Future Directions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (25 July 2023) | Viewed by 7886

Special Issue Editors

Prof. Dr. Ana Caruntu

E-Mail Website
Guest Editor
1. Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Titu Maiorescu University, 031593 Bucharest, Romania
2. Department of Oral and Maxillofacial Surgery, Carol Davila Central Military Emergency Hospital, 010825 Bucharest, Romania
Interests: tissue regeneration; healing; head and neck cancer; biomaterials; inflammation; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Julio Acero

E-Mail Website
Guest Editor
1. Department of Oral and Maxillofacial Surgery, Hospital Ramon y Cajal, 28034 Madrid, Spain
2. Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain
Interests: head and neck cancer; head and neck reconstruction; tissue engineering; microvascular surgery; stem cells; oral cancer; oral surgery; orbital surgery; midfacial surgery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Federico Biglioli

E-Mail Website
Guest Editor
Department of Maxillofacial Surgery, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy
Interests: microsurgery; oral cancer; oral surgery; facial nerve injuries; facial nerve repair; oral and maxillofacial surgery; maxillofacial injuries; reconstructive surgery; craniofacial surgery; facial trauma; facial plastic surgery; facial anomalies; dental implants

Special Issue Information

Dear Colleagues,

Head and Neck Cancer (HNC) encompasses a heterogeneous group of malignancies, arising from the different structures of the head and neck region. Even though most types of HNC are considered preventable, in the context of exposure to known risk factors, the incidence of HNC is steadily increasing. Another important aspect of HNC is the late diagnosis in almost half of the patients, despite efforts to identify accessible diagnostic tools for timely detection. Advanced stages of the disease are associated with dramatic consequences in terms of survival and quality of life. Compared to other types of malignancies, in which novel diagnostic and therapeutic strategies have changed the history of the disease, turning incurable diseases into “curable”, in HNC, the reality is different. Many efforts are made to improve survival, but the results are still far from the expectations. In addition, the functional impairment and social impact for the patient are significant, with a poor quality of life reported by most patients treated in advanced disease stages.

These challenges are a motivation for the medical scientific community to look for innovative solutions in HNC. The multidisciplinary approach is a fundamental element when dealing with these heterogeneous malignancies.  Efforts are continuously made in prevention, early detection, accurate diagnosis and efficient treatment strategies to achieve better disease control and improve the quality of life for HNC patients.

This Special Issue launches an invitation for researchers and clinicians to share their recent investigations and results in the complex field of HNC research. Original articles, review articles, and communications on the topics of prevention, pathogenic mechanisms, biomarkers, diagnosis, clinical aspects, therapy strategies and prognosis in HNC are within the scope of this Special Issue and are welcomed for submission.

Prof. Dr. Ana Caruntu
Prof. Dr. Julio Acero
Prof. Dr. Federico Biglioli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • head and neck squamous cell carcinoma
  • risk factors
  • human papillomavirus
  • morphological markers
  • biomarkers
  • proteomics
  • metabolomics
  • microbiome
  • diagnosis
  • imaging
  • therapeutic approaches
  • clinical trials
  • personalized therapy
  • chemotherapy
  • radiotherapy
  • checkpoint inhibitor
  • immunotherapy
  • surgery
  • minimally invasive surgery
  • precision medicine
  • prognosis
  • quality of life

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

13 pages, 476 KiB  
Review
Oral-Functioning Questionnaires in Patients with Head and Neck Cancer: A Scoping Review
by Matthijs In ’t Veld, Derk H. J. Jager, Chayenne N. Chhangur, Kirsten A. Ziesemer, Frank K. J. Leusink and Engelbert A. J. M. Schulten
J. Clin. Med. 2023, 12(12), 3964; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12123964 - 10 Jun 2023
Cited by 1 | Viewed by 1462
Abstract
Background: Oral-functioning impairment can negatively affect the quality of life (QoL) of head and neck cancer (HNC) patients after receiving radiotherapy (RT). Assessment of patient-reported oral functioning throughout treatment can improve patient care. This scoping review aims to propose a definition for oral [...] Read more.
Background: Oral-functioning impairment can negatively affect the quality of life (QoL) of head and neck cancer (HNC) patients after receiving radiotherapy (RT). Assessment of patient-reported oral functioning throughout treatment can improve patient care. This scoping review aims to propose a definition for oral functioning for HNC patients and to map out the available questionnaires measuring patient-reported oral functioning in RT-treated HNC patients. Methods: A literature search in relevant databases was performed. Each questionnaire was scored on the domains validity, reliability, and responsiveness. Furthermore, the items from the questionnaires were analyzed to define the common denominators for oral functioning in HNC patients. Results: Of the 6434 articles assessed, 16 met the inclusion criteria and employed 16 distinct instruments to evaluate QoL. No questionnaire covered all oral-health-related QoL items nor assessed all aspects of validity, reliability, and responsiveness. Chewing, speaking, and swallowing were the common denominators for oral functioning. Conclusions: Based on the included studies, we suggest using the VHNSS 2.0 questionnaire to assess oral functioning in HNC patients. Furthermore, we suggest to more clearly define oral functioning in HNC patients by focusing on masticatory function (chewing and grinding), mouth opening, swallowing, speaking, and salivation. Full article
(This article belongs to the Special Issue Head and Neck Cancer: Recent Advances and Future Directions)
►▼ Show Figures

Figure 1

25 pages, 972 KiB  
Review
Patient-Reported Outcome Measures of Psychosocial Quality of Life in Oropharyngeal Cancer Patients: A Scoping Review
by Jennifer A. Silver, Russell Schwartz, Catherine F. Roy, Nader Sadeghi and Melissa Henry
J. Clin. Med. 2023, 12(6), 2122; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12062122 - 08 Mar 2023
Cited by 2 | Viewed by 1543
Abstract
Background: Oropharyngeal squamous cell carcinoma (OPSCC) patients are burdened by the effect of the disease process and treatment toxicities on organs important in everyday activities, such as breathing, speaking, eating, and drinking. There is a rise in OPSCC due to human papilloma virus [...] Read more.
Background: Oropharyngeal squamous cell carcinoma (OPSCC) patients are burdened by the effect of the disease process and treatment toxicities on organs important in everyday activities, such as breathing, speaking, eating, and drinking. There is a rise in OPSCC due to human papilloma virus (HPV)-associated OPSCC, affecting younger and healthier patients and with a better overall prognosis. Emphasis must be shared between oncologic outcomes and the effects on quality of life. While there have been efforts to study global and physical quality of life, the impact on psychosocial quality of life has not yet been specifically reviewed. Methods: A scoping review methodology was employed to explore the emotional, social, and mental quality of life in OPSCC patients and determine the impact of HPV status or treatment modalities. Results: Eighty-seven full-text articles were evaluated for eligibility. Fifteen articles met final inclusion criteria. The majority of the studies were conducted in the United States (n = 10) and study methodology was divided between cross-sectional (n = 6), prospective (n = 5), and retrospective studies (n = 4). Four psychosocial quality of life themes were explored: the impact on mental health and emotional wellbeing, social wellbeing and function, stress, and relationship and sexual behavior. Eighteen different patient-reported outcome measures were used, including both general head and neck oncology questionnaires and symptom-specific surveys. Conclusion: There is a paucity of research regarding the effect of OPSCC on patients’ psychosocial quality of life. Learning more about this component of quality of life can guide outreach programs and multidisciplinary involvement in improving patient care. Full article
(This article belongs to the Special Issue Head and Neck Cancer: Recent Advances and Future Directions)
►▼ Show Figures

Figure 1

13 pages, 289 KiB  
Review
Recent Advances, Systemic Therapy, and Molecular Targets in Adenoid Cystic Carcinoma of the Head and Neck
by Ina Dewenter, Sven Otto, Tamara Katharina Kakoschke, Wenko Smolka and Katharina Theresa Obermeier
J. Clin. Med. 2023, 12(4), 1463; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12041463 - 12 Feb 2023
Cited by 6 | Viewed by 2199
Abstract
With an incidence of 3–4.5 cases per million, adenoid cystic carcinoma (ACC) of the head and neck is one of the most common tumors of the parotid and sublingual salivary glands. In the clinical course, ACC is shown to have an aggressive long-term [...] Read more.
With an incidence of 3–4.5 cases per million, adenoid cystic carcinoma (ACC) of the head and neck is one of the most common tumors of the parotid and sublingual salivary glands. In the clinical course, ACC is shown to have an aggressive long-term behavior, which leads to the fact that radical surgical resection of the tumor with tumor-free margins remains the “gold standard” in treating ACC. Particle radiation therapy and systemic molecular biological approaches offer new treatment options. However, risk factors for the formation and prognosis of ACC have not yet been clearly identified. The aim of the present review was to investigate long-term experience of diagnosis and treatment as well as risk and prognostic factors for occurrence and outcome of ACC. Full article
(This article belongs to the Special Issue Head and Neck Cancer: Recent Advances and Future Directions)

Other

Jump to: Review

14 pages, 1857 KiB  
Systematic Review
Can Immunoexpression of Cancer Stem Cell Markers Prognosticate Tongue Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis
by Sayantanee Chaudhury, Swagatika Panda, Neeta Mohanty, Saurav Panda, Diksha Mohapatra, Ravishankar Nagaraja, Alkananda Sahoo, Divya Gopinath, Natalia Lewkowicz and Barbara Lapinska
J. Clin. Med. 2023, 12(8), 2753; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12082753 - 07 Apr 2023
Cited by 3 | Viewed by 1689
Abstract
The objective was to evaluate the association of the immunoexpression of cancer stem cell (CSC) markers with clinicopathological and survival outcomes in tongue squamous cell carcinoma (TSCC) patients. This systematic review and meta-analysis [PROSPERO (CRD42021226791)] included observational studies that compared the association of [...] Read more.
The objective was to evaluate the association of the immunoexpression of cancer stem cell (CSC) markers with clinicopathological and survival outcomes in tongue squamous cell carcinoma (TSCC) patients. This systematic review and meta-analysis [PROSPERO (CRD42021226791)] included observational studies that compared the association of clinicopathological and survival outcomes with CSC immunoexpression in TSCC patients. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were used as outcome measures. Six studies identified the association with three surface markers (c-MET, STAT3, CD44) and four transcription markers (NANOG, OCT4, BMI, SOX2). The odds of early-stage presentation were 41% (OR = 0.59, 95% CI 0.42–0.83) and 75% (OR = 0.25; 95% CI 0.14–0.45) lower in CSC and SOX2 immuno-positive cases than immuno-negative cases, respectively. The odds of well-differentiated tumors in transcription marker immuno-positive cases were 45% lower compared to immuno-negative cases (OR = 0.55, 95% CI 0.32–0.96). The odds of positive lymph nodes were 2.01 times higher in CSC immuno-positive cases compared to immuno-negative cases (OR = 2.01, 95% CI 1.11–3.65). Mortality in immuno-positive cases was 121% higher than that in immuno-negative cases (HR = 2.21; 95% CI 1.16–4.21). Advanced tumor staging and grading, lymph node metastasis, and mortality were significantly associated with positive immunoexpression of CSC markers. Full article
(This article belongs to the Special Issue Head and Neck Cancer: Recent Advances and Future Directions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop